We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+10.59%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$927M
AUM Growth
-$316M
Cap. Flow
-$340M
Cap. Flow %
-36.68%
Top 10 Hldgs %
46.63%
Holding
71
New
14
Increased
9
Reduced
19
Closed
16

Top Buys

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$34.3M
2
PCVX icon
Vaxcyte
PCVX
+$27M
3
CYTK icon
Cytokinetics
CYTK
+$22.3M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$21.8M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$20.9M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$58.1M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$33M
3
XNCR icon
Xencor
XNCR
+$28.4M
4
SLN
Silence Therapeutics
SLN
+$23.7M
5
VERA icon
Vera Therapeutics
VERA
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 96.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
1
IDEAYA Biosciences
IDYA
$3.5B
$66.5M 7.18%
2,100,000
+400,000
+24% +$15.2M
GPCR icon
2
Structure Therapeutics
GPCR
$3.53B
$54.9M 5.92%
1,250,000
+150,000
+14% +$5.8M
RVMD icon
3
Revolution Medicines
RVMD
$40B
$54.4M 5.87%
1,200,000
– –
IRON icon
4
Disc Medicine
IRON
$2.86B
$45.9M 4.96%
935,000
+10,000
+1% +$469K
JANX icon
5
Janux Therapeutics
JANX
$945M
$45.4M 4.9%
1,000,000
+250,000
+33% +$10.9M
OLMA icon
6
Olema Pharmaceuticals
OLMA
$1.07B
$38.3M 4.13%
3,208,875
– –
PCVX icon
7
Vaxcyte
PCVX
$8.05B
$34.3M 3.7%
+300,000
New +$27M
IMVT icon
8
Immunovant
IMVT
$8.27B
$31.4M 3.38%
1,100,000
+525,000
+91% +$15.5M
CLDX icon
9
Celldex Therapeutics
CLDX
$2.83B
$30.6M 3.3%
+900,000
New +$34.3M
OCUL icon
10
Ocular Therapeutix
OCUL
$1.91B
$30.4M 3.29%
3,500,000
-1,650,000
-32% -$13.6M
IONS icon
11
Ionis Pharmaceuticals
IONS
$9.4B
$30M 3.24%
750,000
+450,000
+150% +$20.9M
ERAS icon
12
Erasca
ERAS
$6.63B
$29.8M 3.21%
10,900,000
+5,000,000
+85% +$14.1M
APLS
13
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$28.8M 3.11%
1,000,000
-1,000,000
-50% -$37M
MRUS
14
DELISTED
Merus
MRUS
$28.7M 3.1%
575,000
-275,000
-32% -$14.4M
LKFT
15
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.85B
$23M 2.49%
+800,000
New +$21.8M
AKRO
16
DELISTED
Akero Therapeutics
AKRO
$23M 2.48%
800,000
– –
DSGN icon
17
Design Therapeutics
DSGN
$748M
$22.7M 2.45%
4,217,627
-814,874
-16% -$3.83M
VERA icon
18
Vera Therapeutics
VERA
$2.57B
$22.1M 2.38%
500,000
-450,000
-47% -$17.1M
COGT icon
19
Cogent Biosciences
COGT
$6.95B
$21.6M 2.33%
+2,000,000
New +$19.5M
CYTK icon
20
Cytokinetics
CYTK
$10.9B
$21.1M 2.28%
+400,000
New +$22.3M
BCAX
21
Bicara Therapeutics
BCAX
$1.84B
$20.4M 2.2%
+800,000
New +$20.4M
SRPT icon
22
Sarepta Therapeutics
SRPT
$1.7B
$18.7M 2.02%
150,000
– –
ANNX icon
23
Annexon
ANNX
$867M
$15.4M 1.66%
2,600,000
-700,000
-21% -$4.15M
TVTX icon
24
Travere Therapeutics
TVTX
$5.37B
$15.4M 1.66%
+1,100,000
New +$11.5M
ELVN icon
25
Enliven Therapeutics
ELVN
$3.93B
$12.6M 1.36%
495,000
-100,000
-17% -$2.32M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2024 Portfolio in Review

As of Q3 2024, Logos Global Management held 71 positions worth $927M, down 25% from $1.24B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Logos Global Management withdrew a net $340M in Q3 2024, closing 16 positions and reducing 19 holdings. Its most notable exit was argenx, an estimated $58.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 70% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Celldex Therapeutics worth $30.6M.

  • Logos Global Management's largest Q3 2024 buy was Celldex Therapeutics: 900,000 shares worth $30.6M.
  • Logos Global Management added most to Ionis Pharmaceuticals in Q3 2024, an estimated $20.9M increase.
  • Logos Global Management's biggest Q3 2024 reduction was Silence Therapeutics, cutting an estimated $23.7M.
  • Logos Global Management fully exited argenx in Q3 2024, selling an estimated $58.1M.
  • Logos Global Management's ten largest holdings make up 47% of its $927M portfolio in Q3 2024.
  • Logos Global Management opened 14 new positions and closed 16 in Q3 2024.
  • Logos Global Management's portfolio value fell 25% quarter-over-quarter to $927M.

Based on Logos Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.